|[June 10, 2014]
Arrowhead to Present at Upcoming Investor Conferences
PASADENA, Calif. --(Business Wire)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that it
will present at two upcoming investor conferences.
Scheduled presentations include the following:
Wells Fargo (News - Alert) 2014 Healthcare Conference - Boston
June 17, 2014 - At 1:45 p.m. EDT Christopher Anzalone, Ph.D.,
President and Chief Executive Officer, will deliver a corporate
presentation, and at 2:20 p.m. EDT he will participate in the "Gene
Manipulation" panel discussion
Piper Jaffray GenomeRx Symposium - New York
June 23, 2014 - At 3:30 p.m. EDT David Lewis, Ph.D., Chief
Scientific Officer, will participate in the "RNA/DNA: Getting It Where
You NeedIt" panel discussion
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silences disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead's pipeline includes clinical
programs in chronic hepatitis B virus and partner-based programs in
obesity and oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter (News - Alert) @ArrowRes.
To be added to the Company's email list to receive news directly, please
send an email to email@example.com.
[ InfoTech Spotlight's Homepage ]